54.65
+0(+0.00%)
Currency In USD
Address
601 Gateway Boulevard
South San Francisco, CA 94080
United States of America
Phone
650 487 6488
Website
Sector
Healthcare
Industry
Biotechnology
Employees
69
First IPO Date
June 20, 2019
| Name | Title | Pay | Year Born |
| Andrew Cheng | President, Chief Executive Officer & Director | 1.1M | 1967 |
| Scott A. Gangloff | Chief Technical Officer | 558,641 | 1974 |
| Jonathan Young | Co-Founder, Executive Vice President, Chief Operating Officer & Secretary | 710,500 | 1970 |
| Catriona Yale | Executive VP & Chief Development Officer | 716,300 | 1972 |
| Timothy Rolph | Co-Founder & Chief Scientific Officer | 722,315 | 1954 |
| William R. White | Executive Vice President, Chief Financial Officer, Treasurer & Head of Corporate Development | 739,500 | 1973 |
| John J. Schembri | Senior VP & Head of Finance | 0 | 1962 |
| Patrick Lamy | Senior Vice President of Commercial Strategy | 0 | 1973 |
| Thomas Ross | Senior VP & Head of Legal | 0 | N/A |
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
